Efficacy and safety of anti-vascular endothelial growth factor agents on corneal neovascularization: A meta-analysis  

作　　者：Shih-Chung Lai El-Wui Loh Du-I Chiou Chien-Tai Hong 

机构地区：[1]Department of Ophthalmology,Shuang Ho Hospital,New Taipei City 23561,Taiwan,China [2]Center for Evidence-Based Health Care,Department of Medical Research,Taipei Medical University Shuang Ho Hospital,New Taipei City 23561,Taiwan,China [3]Cochrane Taiwan,Taipei Medical University,Taipei 110,Taiwan,China [4]Graduate Institute of Clinical Medicine,College of Medicine,Taipei Medical University,Taipei 110,Taiwan,China [5]Department of Medical Imaging,Taipei Medical University Shuang Ho Hospital,New Taipei City 23561,Taiwan,China [6]Department of Neurology,Taipei Medical University-Shuang Ho Hospital,New Taipei 23561,Taiwan,China

出　　处：《World Journal of Clinical Cases》2023年第30期7337-7349,共13页世界临床病例杂志

摘　　要：BACKGROUND Corneal neovascularization(CoNV)is the second major cause of blindness.Vascular endothelial growth factor(VEGF)inhibitors,e.g.,bevacizumab,have been used to prevent CoNV.AIM We conducted an updated systematic review and meta-analysis of clinical trials to examine the efficacy and safety of anti-VEGF in CoNV.METHODS A literature search was conducted using three electronic databases.Mean difference(MD),standard mean difference(SMD),and relative risk(RR)are used to estimate the effect size.RESULTS Nine randomized controlled and three non-randomized trials were obtained.The pooled results demonstrated a significant reduction of CoNV area/Length(SMD=-1.17,95%CI:-1.58 to-0.75),best corrected visual acuity(MD=-0.54,95%CI:-0.91 to-0.17),and graft rejection(RR=0.44,95%CI:0.24 to 0.8)and failure(RR=0.39,95%CI:0.19 to 0.78)rates in the anti-VEGF group than the placebo group.A non-significant reduction of the epithelial defect was also observed in the bevacizumab group compared with the placebo(RR=0.56,95%CI:0.30 to 1.06).Compared with a placebo,the unsynthesizable trials also support that bevacizumab improves visual acuity,CoNV,graft rejection,and failure rates.Trials reporting other comparisons revealed the superiority of combined remedy with bevacizumab compared to other treatments in reducing CoNV.CONCLUSION Anti-VEGF agents,mainly bevacizumab,are an effective and safe treatment for CoNV of all causes and prevent corneal graft rejection and failure in corneal transplantation.

关 键 词：EFFICACY SAFETY Anti-vascular endothelial growth factor agents Corneal neovascularization BEVACIZUMAB 

分 类 号：R743.3[医药卫生—神经病学与精神病学]